Navigation Links
Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
Date:11/4/2008

- Company Also Announces Participation in Upcoming Investor Conferences in

November -

SAN DIEGO, Nov. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders, today announced its active calendar of events for November 2008, which includes the teleconference and webcast of its third quarter 2008 financial results as well as upcoming corporate presentations at noteworthy investor conferences.

On November 6, 2008 at 5:00 p.m. Eastern time, Orexigen management will host the call and webcast to discuss the financial results for the third quarter ended September 30, 2008, and recent business highlights. The live call may be accessed by calling 800-860-2442 (domestic) or 412-858-4600 (international). The webcast can be accessed live on the investor relations section of the Company's web site at http://www.orexigen.com and will be archived for 14 days following the call.

Upcoming Corporate Presentations

Rodman & Renshaw 10th Annual Healthcare Conference

New York Palace Hotel, New York

November 11, 2008

2:00 p.m. EST

Lazard Capital Markets 5th Annual Healthcare Conference

St. Regis Hotel, New York

November 18, 2008

11:25 a.m. EST

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity and other central nervous system-related disorders. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Arno Therapeutics Appoints William F. Hamilton to Board of Directors
4. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
5. Duska Therapeutics Acquires Technology for ATPotent Sperm Motility Program
6. ConvaTec Names Presidents of Wound Therapeutics and Ostomy Care Business Units
7. Preliminary Clinical Data Presented at the 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics Demonstrate Superior Profile of S*BIOs Novel Anti-Cancer Drug SB939
8. Synvista Therapeutics Appoints William Federici to its Board of Directors
9. LaVoie Group Adds Cancer Therapeutics Company, Neotropix(R),to Its Life Science Agency Roster
10. Cell Therapeutics Regains Compliance with NASDAQs Minimum Bid Price Requirement
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... Los Angeles-based weight loss surgeon ... TV’s “Mama June: From Not to Hot,” which will begin airing on February 24, ... known to millions from the 2012 reality television series, “Here Comes Honey Boo Boo.” ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, ... relations, content marketing, social media management, corporate communications, SEO and cause marketing, is ... and in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC announces ... and explore the world from different perspectives. By providing a place for people ... understanding, increase empathy, and find greater happiness. , "Our approach to structuring ...
(Date:2/23/2017)... ... , ... Current Meditation , a new meditation concept ... U.S. starting this spring. Current Meditation focuses on “meditation for the modern world,” ... will be the first meditation concept in the U.S. offering franchising opportunities, setting ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... drug pricing data and benchmarks in the global Oesophageal Cancer market. ... What are the key drugs marketed for Oesophageal Cancer ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets ... & Trends - Industry Forecast to 2025" report to their ... The ... around 6.9% over the next decade to reach approximately $47.6 billion ... estimates and forecasts for all the given segments on global as ...
Breaking Medicine Technology: